The Ready, Set, PrEP program is designed to provide Gilead Sciences' Truvada and Descovy to up to 200,000 people who do not have prescription drug insurance coverage. Gilead is donating supplies of both drugs.
BioCentury reported that the the nomination of radiation oncologist Dr. Stephen Hahn, who had been under consideration, would follow an FBI background check. Acting Commissioner Ned Sharpless and Brett Giroir, an assistant HHS secretary, had also reportedly been in the running.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
President Donald Trump must appoint a new commissioner of the FDA by Nov. 1. Ned Sharpless has served as acting commissioner since Scott Gottlieb's departure in March.
John O'Brien, a former insurance industry executive, will step down less than one year after his appointment as senior advisory to HHS Secretary Alex Azar on drug-pricing reform. He had worked for HHS since March 2017 and also previously worked for CMS.
The administration's plan to lower drug costs met two major setbacks last week. Experts weighed in on what that could mean.
The Washington Post and other outlets reported that the administration has withdrawn a proposal to end rebates between pharmacy benefit managers and drugmakers.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
District Court Judge Amit Mehta ruled Monday that the Department of Health and Human Services lacked the authority to impose the rule, which it adopted in May.
U.S. District Judge Amit Mehta in Washington, D.C. ruled in favor of pharma companies challenging the rule in court because of what he said was a lack of statutory authority from the HHS to govern drug marketing.
Amgen, Eli Lilly and Merck - plus the Association of National Advertisers - said in a complaint filed Friday that the law would mislead consumers, overstep the government's authority and violate the First Amendment.
In a statement, the agency said that a decision on whether to have Medicare cover the cell therapies would not be issued Friday, but would be forthcoming.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The changes will take place 60 days after the rule is published in the Federal Register. Industry trade group PhRMA have opposed the rule, saying it will lead to consumer confusion and sticker shock that could discourage medication use.
Sharpless, the director of the National Cancer Institute, was reportedly favored by HHS Secretary Alex Azar as outgoing Commissioner Scott Gottlieb's successor.
Gottlieb, who is expected to step down in about a month, leaves behind a unique legacy and will likely be difficult to replace.
Through the Emergency Triage, Treat and Transport model, CMS will pay ambulance suppliers and providers to transport Medicare beneficiaries to an alternative location (like an urgent care clinic) and to provide treatment in place with a practitioner.
Another proposal, to revoke safe-harbor protections under the Anti-Kickback Statute for biopharma-PBM rebates, drew praise from speakers in a panel at the BIO CEO & Investor Conference Tuesday.